NICE changes it’s tune about cabazitaxel

According to news reports this morning, the National Institute for Health and Care Excellence (NICE) in England has changed its tune about covering cabazitaxel (Jevtana) as a treatment for men with metastatic, castration-resistant prostate cancer (mCRPC).

Apparently, NICE was persuaded to change its mind after Sanofi agreed to cut the cost to the National Health System  — although the size of the discount from the UK list price of £3,696 per vial (equivalent to about US$5313 per vial) was not mentioned in this report on European Pharmaceutical Review.

However, NICE is still limiting the use of cabazitaxel among men with mCRPC to the following situations and criteria:

  • Cabazitaxel  + prednisone or prednisolone is recommended only for men who
    • Have an ECOG performance score of 0 or 1
    • Have already been treated with at least 225 mg/m2 of docetaxel
  • Treatment with cabazitaxel must be stopped if and when either of the following occurs
    • The patient progress while on cabazitaxel therapy
    • The patient has received a maximum of 10 cycles of cabazitaxel therapy

According to a quote from a senior employee of NICE mentioned in the above report, NICE appears to be very pleased that their tough negotiating stance with Sanofi has produced this result: we suspect that the discount agreed to by Sanofi is substantial.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.

%d bloggers like this: